Abstract | INTRODUCTION: METHODS: Anti-HNK1 antibodies were assessed with the GanglioCombi™ MAG ELISA test (Buhlmann) in 41 anti-MAG neuropathies and in 118 controls: 34 chronic inflammatory demyelinating polyradiculoneuropathies, 3 Miller Fisher syndromes, 12 sensory neuronopathies, 63 length-dependent axonal sensory polyneuropathies, 6 healthy controls. Anti-HNK1 antibody was tested before and 1 year after rituximab therapy in seven patients with anti-MAG neuropathy. RESULTS: Anti-HNK1 antibodies were positive in 40/41 anti-MAG neuropathies, and in 1/118 controls (sensitivity 98%, specificity 99%). Only considering controls with IgM paraprotein, specificity was 96% (23/24). In anti-MAG neuropathies, anti-HNK1 titre was correlated with sensory deficiency evaluated with the INCAT sensory sum score (r = 0.4, p = 0.01) and with disability evaluated with the Rasch-built Overall Disability Scale (r = [Formula: see text] 0.4, p = 0.01) and Overall Neuropathy Limitation Scale (r = 0.4, p = 0.02). Anti-HNK1 titres were not related to age, disease duration, atypical clinical features and anti-MAG antibodies titres. Anti-MAG titres were not associated with disease severity. Anti-HNK1 titres were decreased by 18% 1 year after rituximab treatment. CONCLUSIONS: Anti-HNK1 antibodies have good sensitivity and specificity for the diagnosis of anti-MAG neuropathy. Interestingly, anti-HNK1 titres are related to the disease severity and decrease after rituximab infusions.
|
Authors | Emilien Delmont, Shahram Attarian, Jean-Christophe Antoine, Stephane Paul, Jean Philippe Camdessanché, Aude-Marie Grapperon, Alexandre Brodovich, Jose Boucraut |
Journal | Journal of neurology
(J Neurol)
Vol. 266
Issue 8
Pg. 1973-1979
(Aug 2019)
ISSN: 1432-1459 [Electronic] Germany |
PMID | 31089861
(Publication Type: Journal Article)
|
Chemical References |
- Autoantibodies
- Biomarkers
- CD57 Antigens
- MAG protein, human
- Myelin-Associated Glycoprotein
|
Topics |
- Aged
- Aged, 80 and over
- Autoantibodies
(blood)
- Biomarkers
(blood)
- CD57 Antigens
(blood)
- Disease Management
- Female
- Humans
- Male
- Middle Aged
- Myelin-Associated Glycoprotein
(blood)
- Peripheral Nervous System Diseases
(blood, diagnosis, therapy)
|